» Articles » PMID: 35003797

Neurophysiological Mechanisms of Cancer-induced Bone Pain

Overview
Journal J Adv Res
Date 2022 Jan 10
PMID 35003797
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Cancer-induced Bone Pain (CIBP) is an important factor affecting their quality of life of cancer survivors. In addition, current clinical practice and scientific research suggest that neuropathic pain is a representative component of CIBP. However, given the variability of cancer conditions and the complexity of neuropathic pain, related mechanisms have been continuously supplemented but have not been perfected.

Aim Of Review: Therefore, the current review highlights the latest progress in basic research on the field and proposes potential therapeutic targets, representative drugs and upcoming therapies.

Key Scientific Concepts Of Review: Notably, factors such as central sensitization, neuroinflammation, glial cell activation and an acidic environment are considered to be related to neuropathic pain in CIBP. Nonetheless, further research is needed to ascertain the mechanism of CIBP in order to develop highly effective drugs. Moreover, more attention needs to be paid to the care of patients with advanced cancer.

Citing Articles

Anwulignan Alleviates Bone Cancer Pain by Modulating the PPARα/CXCR2 Signaling Pathway in the Rat Spinal Cord.

Wang Y, Liu Q, Jiang Y, Mao L, Zoubaa M, Wang J CNS Neurosci Ther. 2025; 31(3):e70302.

PMID: 40079428 PMC: 11904945. DOI: 10.1111/cns.70302.


Impact of the Number of Administered Systemic Treatment Lines on Local Response to Radiation Therapy for Multiple Myeloma.

Guerini A, Mataj E, Borghetti P, Triggiani L, Pegurri L, Nici S Adv Radiat Oncol. 2025; 10(3):101696.

PMID: 39911722 PMC: 11795776. DOI: 10.1016/j.adro.2024.101696.


Mechanisms of Cancer-Induced Bone Pain.

Wang X, Li L, Wang Y J Pain Res. 2025; 18:315-326.

PMID: 39867539 PMC: 11760761. DOI: 10.2147/JPR.S498466.


Emerging advances in drug delivery systems (DDSs) for optimizing cancer complications.

Li K, Guo B, Gu J, Ta N, Gu J, Yu H Mater Today Bio. 2025; 30:101375.

PMID: 39759851 PMC: 11699619. DOI: 10.1016/j.mtbio.2024.101375.


AIM2 promotes excitatory glutamate receptor expression by inhibiting STING and contributes to bone cancer pain in male mice.

Wang L, Xu X, Su S, Li B, Zhang K, Yu X Sci Rep. 2024; 14(1):31851.

PMID: 39738518 PMC: 11685590. DOI: 10.1038/s41598-024-83027-w.


References
1.
Yoneda T, Hiasa M, Okui T . Crosstalk Between Sensory Nerves and Cancer in Bone. Curr Osteoporos Rep. 2018; 16(6):648-656. DOI: 10.1007/s11914-018-0489-x. View

2.
Jimenez-Andrade J, Ghilardi J, Castaneda-Corral G, Kuskowski M, Mantyh P . Preventive or late administration of anti-NGF therapy attenuates tumor-induced nerve sprouting, neuroma formation, and cancer pain. Pain. 2011; 152(11):2564-2574. PMC: 3199350. DOI: 10.1016/j.pain.2011.07.020. View

3.
Wemmie J, Price M, Welsh M . Acid-sensing ion channels: advances, questions and therapeutic opportunities. Trends Neurosci. 2006; 29(10):578-86. DOI: 10.1016/j.tins.2006.06.014. View

4.
Zhou Y, Liu D, Chen S, Sun J, Zhou X, Rittner H . Reactive oxygen species scavengers ameliorate mechanical allodynia in a rat model of cancer-induced bone pain. Redox Biol. 2017; 14:391-397. PMC: 5650652. DOI: 10.1016/j.redox.2017.10.011. View

5.
Niiyama Y, Kawamata T, Yamamoto J, Omote K, Namiki A . Bone cancer increases transient receptor potential vanilloid subfamily 1 expression within distinct subpopulations of dorsal root ganglion neurons. Neuroscience. 2007; 148(2):560-72. DOI: 10.1016/j.neuroscience.2007.05.049. View